NCT04631978

Brief Summary

Cachectic patients and controls undergoing a comprehensive ophthalmologic examination. The imaging of all subjects is undertaken using a commercial OCTA device with a scan rate of 70,000 A-scans/s, scan beam wavelength of 840 ± 10 nm and bandwidth of 45 nm. All measurements are performed between 10:00 and 12:00 on the same day. The OCTA images are independently graded and assessed by two retinal specialists. The software automatically segmented these full-thickness retinal scans into the superficial and deep inner retinal vascular plexuses, outer retina, and choriocapillaris (CC). The vascular density in the superficial and deep retinal vascular zones is calculated automatically by the software, and the foveal avascular zone (FAZ) and foveal density (FD) are also automatically determined. Choroidal thickness is calculated manually by two retinal specialists, and the average value was used.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
48

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jun 2020

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2020

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 30, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 30, 2020

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

November 11, 2020

Completed
6 days until next milestone

First Posted

Study publicly available on registry

November 17, 2020

Completed
Last Updated

November 18, 2020

Status Verified

November 1, 2020

Enrollment Period

3 months

First QC Date

November 11, 2020

Last Update Submit

November 17, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • Choriocapillaris flow area

    Choriocapillaris flow area assessed with optical coherence tomography angiography

    10 minutes

Secondary Outcomes (4)

  • Subfoveal choroidal thickness

    10 minutes

  • Vessel density

    10 minutes

  • Foveal avascular zone

    10 minutes

  • Subfoveal central macular thickness

    10 minutes

Study Arms (2)

Underweight

Comprehensive ophthalmologic examination

Diagnostic Test: Comprehensive ophthalmologic examination

Control

Comprehensive ophthalmologic examination

Diagnostic Test: Comprehensive ophthalmologic examination

Interventions

Measurements of best-corrected visual acuity, refractive error, intraocular pressure, axial length, slit lamp examination of the anterior segment, dilated fundus examination, and optical coherence tomography angiography imaging.

ControlUnderweight

Eligibility Criteria

Age18 Years - 40 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Study population includes a convenience sampling from the patients admitted to outpatient clinic between June 2020 and August 2020.

You may qualify if:

  • Underweight (BMI \< 18.50 kg/m2).

You may not qualify if:

  • refractive error \>+3.0 diopters (D) or \<-3.0 D spherical equivalent;
  • poor image quality \<60 due to unstable fixation
  • IOP \> 21 mm Hg
  • longer AL (\>25 mm)
  • pre-existing ophthalmic pathologies
  • prior ocular surgery
  • a systemic chronic disease that can cause underweight or retinopathy, such as cancer, malnutrition, and diabetes mellitus.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Aslı Çentinkaya Yaprak

Antalya, 070059, Turkey (Türkiye)

Location

MeSH Terms

Conditions

CachexiaThinness

Condition Hierarchy (Ancestors)

Weight LossBody Weight ChangesBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

November 11, 2020

First Posted

November 17, 2020

Study Start

June 1, 2020

Primary Completion

August 30, 2020

Study Completion

August 30, 2020

Last Updated

November 18, 2020

Record last verified: 2020-11

Data Sharing

IPD Sharing
Will not share

Locations